In this lecture, I shall discuss our early research on neutron capture therapy over a number of years, beginning in 1950, speaking briefly of patient treatments but dwelling mostly on interpretations of our animal experiments.
Prologue
In this lecture, I shall discuss our early research on neutron capture therapy over a number of years, beginning in 1950, speaking briefly of patient treatments but dwelling mostly on interpretations of our animal experiments.
This work was carried out over eighteen years, beginning over forty years ago (1) In the spring of 1950 we began screening vital dyes to use as a target unit for what was to be known as neutron capture therapy. Since some dyes have an almost specific affinity for malignant tumors, the use of such as a carrier of the target atom appeared to be advantageous, whatever target atom or reaction was sought. For the dye, I chose bismarck brown, which had most of the desired characteristics. Winton Steinfield joined our group in only was it easy for Sweet and me to agree to a joint study on the application of this reaction in the treatment of glioblastoma multiforme, but Fox was also willing to modify the shielding on the top of the BGRR to give us a facility for patient trials. 
Clinical Studies
William Sweet and his colleagues had some data on the distribution of boron between brain and tumor during a short period after injection. These data seemed to indicate that there was a very sharp rise in tumor boron concentration after injection, peaking within a few minutes and then falling abruptly. With this knowledge in hand, a series of studies was begun at the Medical Department on the time course of boron neutron-capture effects on the pig. Radiation effects were evident in the exposed regions of these animals.
This was really the first demonstration at Brookhaven of in vivo effects of this reaction (8, 9 together with Stuart Lippincott of Brookhaven National Laboratory (7, 8, 9) .
Each independently evaluated the effects of neutron capture therapy in those patients. Discouragingly, in no case did anyone find specific changes characteristic of radiation exposure which could be expected after neutron capture therapy (17, 18, 19, 20, 21, 22) . The findings in this major extension of patient studies were in full agreement with Brookhaven's John Godwin's postmortem appraisal of the first eight patients receiving this treatment (14). I can attest to the careful, meticulous studies carried out by these experts because I, too, examined the specimens which were specially prepared to bring out any unusual histopathological effects.
Experimental Studies
Using the Medical Department's port at the graphite reactor in the mid-1950s, Konikowski and I began our extensive series of studies on neutron capture therapy in mice. The malignant methylcholanthrene-induced transplantable tumor, induced by Hale, was the object of our studies with pentaborate as the boron-10 carrier. Thus began the experiments to gain more information on boron distribution and radiation effects so that the most potent borate dose and neutron fluence could be selected. We also sought to learn if various residence times of boron in the tumor before irradiation changed the degree of tumor regression after the treatment. The first experimental neutron capture trials used young mice with intracranial tumor implants. When the tumors had grown sufficient^' to be easily detected, a borate injection was given intravenously in a tail vein. The mouse then was exposed to an adequate thermal neutron fluence. Three days later, the animal was killed and the tumor tissue residue, or what was believed to be that, was removed and minced using sterile precautions. The separated tumor cells were then injected intracranially into ten mice. If none of the mice died from tumors, the result was positive. But with ten animals injected for each exposed tumor, the logistics became difficult, for this meant injecting one hundred test mice for ten treated ones. Another disadvantage was that all tumor remnants were lost by the mincing, leaving none for histological study.
We then tried implantation of the tumor into thigh muscles. After no longer than three weeks, death resulted from tumor growth. Growth was rapid in ten to twelve days to diameters averaging 1.0 centimeters, and in this period no central necrosis was ever found; thus, the tumor was a useful tool for this study, for it could be used, in part, for chemical analysis, still leaving adequate specimens for histological appraisal. A viable brain-tobrain mouse tumor colony was maintained by intracranial implantation of 0.02 ml of inoculum in 4-to-6-week old mice every eight days which contained equal parts of minced tumor and saline. It also could be used for a thigh intramuscular transplant. The intracerebral take rate was 90% to 100%. When this tumor preparation was implanted in the thigh, 0.06 ml was used.
Thereafter, two successive thigh-thigh transplants furnished experimental material. Minced thigh tumor mixed with an equal amount of saline provided the 0.06 ml inoculum. The thigh tumor take rate in this methodology was 79% to 90% (7) . If thigh-to-thigh transplants were continued, it was found that tumor invasiveness increased. To maintain constant invasiveness, after two thigh-tothigh transplants, the next transplant used a brain tumor preparation and the above-referenced protocol was followed. This general procedure was followed throughout the entire period of experimentation. A viable mouse tumor, free of visible necrosis, was maintained by thigh or brain transplantation in 4-to-6-week old mice every eight days. Since our criteria for evaluation of the treatment were based on an assumption of an intact tumor, necrosis introduced an uncertainty in classifying results, as it falsified the amount of tumor mass actually present. At the same time, the tumor had to be kept free of viral and bacterial contaminants, a most demanding task. The animals used in specific experiments received thigh implants with enough animals being inoculated to provide in addition a small group for tumor colony maintenance By 1968 we had accumulated a massive amount of data and studies on the effect of varying the interval between injection and exposure were in progress. But we had no assurance that we could rightfully use all the data or even any specific part in a summation analysis. We were eager to learn if there were demonstrable differences in the results when different reactors were used with different exposure times, from over 20 minutes at the BGRR to one hundred milliseconds at the TRIGA pulsed reactor. The extensive studies at the BMRR fell between these extremes, at 100 to 300 seconds.
Up to this time we had routinely calculated entrance fluence by measuring activation of gold wires inserted in various segments of the mouse thigh tumor. Useful as these experiments had been, they gave no information on the effect of various tumor diameters upon outcome. We had neglected approximation of exit dose studies at presumably maximum diameters. These we now determined to examine. Fortunately, in all of our tests, we had implanted gold wires and foils distal to the neutron flux entrance, so their activation gave a better measurement to establish the effective average neutron fluence to the most distant region of the tumor. These so-called exit data were now The values for f range from 0.44 for a tumor 8 mm in maximum depth, to 0.32 for an 11 mm-deep tumor, to 0.26 for a 13 mm-deep tumor, and so on.
We were also interested in estimating the radiation dose at the deepest margin of the tumor. The Exit Rad Index is a convenient index with which we can compare our numerous experimental trials. ERI must be some approximation to the minimum dose or the dose at the exit of the slow neutron beam as it passed through the tumor, although we did not explore this aspect of dosimetry further.
When we plotted all the data from the various studies using the Exit Rad Index as the reference dose unit, we observed that the data for different doses at different reactors showed a remarkable fit to a standard format (26) [ In every experiment that we carried out, the animals treated had tumors of various diameters. Consequently, we do not have a single experiment in which all animals showed permanent regression (cure) of the tumor. This result could have been attained by restricting a study to tumors of a single diameter less than 1.0 cm, but that would not have been as informative as using tumors of multiple sizes. It is important to remember that these studies were done over almost two decades, using a variety of reactors, at several of which rather makeshift or jerry-built devices were used to hold the animals for irradiation. Taking into account the general factor of biological variation, the graphs show, gratifyingly, a consistent, uniform pattern. This uniformity bespeaks a validity for using all of our data when we examine the totality of results for their compatibility with our original hypotheses.
It is now evident that the most significant of all our studies was the one in which we observed the effects using a series of ten-minute sequences for beginning the exposure after boron injection. Before these experiments, we could only predict most generally the outcome in any situation. We had noted that this seemed to be in some way related to the time of exposure after injection, but there was no good evidence to sustain this contention. When data from such studies became available, we learned that despite a flat boron concentration in the tumor after the first ten minutes (we irradiated no animals before ten minutes after injection), the incidence of complete regression of tumors in the exposed population changed remarkably with each sequential injection-exposure time interval. For the groups shown in Figure   7 , the number of animals ranged from 53 to 112. For the group exposed from 7 to 11 minutes after injection, 58% showed a complete regression of their tumor; among the group exposed 13 to 23 minutes after injection, 702 showed complete regression of their tumors; in the 25 to 36-minute group, 75% showed complete regression. The mice in the 38 to 48-minute group showed the maximum response of 86% with complete regression. Thereafter, there was a stepwise decline for the 50 to 60-minute group to 582, the 62 to 72-minute group to 502, the 74 to 80-minute group to 26%, and the 82 to 92-minute group to 22%.
We found this pattern could also be described for each boron dose that we used (27) . From this information, we know that some observations in previous studies believed to be deviations were not necessarily due to experimental The results at the BGRR and at the BMRR show a pleasing consistency.
When we take into account the marked differences in durations of exposure, over 20 minutes at the BGRR and only 23 to 300 seconds at the BMRR, it becomes clear why we did not anticipate such similarity. There is no reason to believe that similar, stepwise-effects would not have occurred at the BGRR had we used variable injection-exposure time in intervals there. It was by pure chance that we began exposure at the BGRR at an interval that was the most effective for tumor regression. I suspect that the scatter of results in the TRIGA experiments was due in large part to uncertainty in placing the animals in the path of the beam. Yet, taking all this into account, as well as the small number of animals exposed at the TRIGA pulsed reactor in a fraction of one second, there are no good grounds for believing that the 300-millisecond TRIGA exposures were any more efficacious than the BMRR exposures.
Discussion
One major puzzle which these data present can be stated succinctly. The 10 B(n,a) 7 Li reaction must occur when thermal neutrons come into juxtaposition to a boron-10 atom. Yet, when these data are examined with respect to complete tumor regression following several different injection-radiation intervals, a paradox is evident. Tumor elimination was not consistent with the observed boron concentration and ths neutron fluence. This inconsistency is clearly shown in Figure 7 , and is also suspected from a study of various relationships between the ERI and the probability of tumor regression. In hypertrophy has gone. When much larger radiation exposures were given to the skin than were used in these studies, both epilation and scarring followed, yet exposures of this intensity caused no changes in muscle tissue sections taken from exposure sites.
How can we explain these paradoxes? Our data give no clue to the answer.
There are a number of possible hypotheses which come to mind, but in the absence of much more data on the pharmacodynamics and pharmacokinetics of the borate ion, no selection among these hypotheses can be made today.
Epilogue I look to researchers at Brookhaven National Laboratory to continue work on experimental neutron capture therapy and its application to patient therapy. In so doing, I trust you will explain the paradoxes I have outlined.
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